Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Program: Scientific Session
General Topic: Clinical

Cancer Immunotherapy and Its Toxicities, Today and Tomorrow

Monday, October 27, 2025
4:00 PM – 5:00 PM Central Time

    Moderator(s)

  • Jeffrey Sparks, MD, MSc

    Brigham and Women's Hospital
    Boston, Massachusetts, United States

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Amgen: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing)

  • Sophia Weinmann, MD, FACR

    Duke University
    Durham, North Carolina, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

    • Session Coordinator(s)

  • Janet Pope, MD, FRCPC, MPH

    University of Western Ontario
    London, ON, Canada

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer-Ingelheim: Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Horizon: Advisor or Review Panel Member (Ongoing); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sandoz: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sanofi: Consultant (Ongoing); Therakos: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Zura: Consultant (Ongoing)

  • Brittany Adler, MD

    Johns Hopkins University
    BALTIMORE, Maryland, United States

    Disclosure information not submitted.

This session of the 2025 Advances in Cancer Immunotherapy™ series is presented in collaboration with the Society for Immunotherapy of Cancer (SITC). This session will provide a comprehensive overview of Immune Checkpoint Inhibitor (ICI) toxicities from both an oncologic and rheumatologic perspective. An oncologist will first discuss the evolving landscape of ICIs, their mechanisms of action, and the spectrum of toxicities encountered in clinical practice. A rheumatologist will then address the evaluation and management of ICI-induced rheumatic irAEs. Through case-based discussions, attendees will gain practical insights into recognizing, diagnosing, and treating these complications to optimize patient care in a multidisciplinary setting.

Learning Objectives:

  • Delineate the current uses of cancer immunotherapy for different tumor types
  • Examine the risk of autoimmune disease flare or de novo irAE after ICI for patients with rheumatic disease
  • Recognize the risks and benefits of systemic steroids and certain steroid-sparing medications for patient with ICI-inflammatory arthritis
  • Create a management plan for a patient with a severe/refractory irAE (like ICI-sicca) or rare irAE

Presentations:

  • 4:00 PM – 4:30 PM Central Time
    Current Cancer Immunotherapy Landscape and the Future

    Speaker: Aliyah Pabani, MD, MPH – Johns Hopkins

  • 4:30 PM – 5:00 PM Central Time
    When Cancer Therapy Triggers Autoimmunity: The Rheumatologist’s Role in Immune Checkpoint Inhibitors Toxicity

    Speaker: Elad Sharon, MD,MPH – Dana-Farber Cancer Institute